-
Bulletin of the New York Academy of... Apr 1951
Topics: Connective Tissue; Humans; Rheumatic Diseases
PubMed: 14821704
DOI: No ID Found -
British Medical Journal Jul 1949
Topics: Rheumatic Diseases
PubMed: 18134852
DOI: 10.1136/bmj.2.4620.201 -
British Medical Journal Dec 1957
Topics: Disease; Giant Cell Arteritis; Humans; Muscles; Muscular Diseases; Polymyalgia Rheumatica; Rheumatic Diseases
PubMed: 13489270
DOI: No ID Found -
Zeitschrift Fur Rheumatologie Oct 2022Various research groups at the German Rheumatism Research Center in Berlin, in close cooperation with the Department of Rheumatology and Clinical Immunology of the... (Review)
Review
Various research groups at the German Rheumatism Research Center in Berlin, in close cooperation with the Department of Rheumatology and Clinical Immunology of the Medical Clinic at the Charité, have made important contributions to the significance of B cells and plasma cells in rheumatic diseases, which are relevant not only for rheumatology but for all clinical specialties in which antibody-mediated diseases play a role. In particular, the research addresses impaired B cell homeostasis, the importance of the IgM Fc receptor in the regulation of autoimmunity, the role of long-lived memory plasma cells in maintaining autoimmunity and ensuring its survival in specific niches organized by stromal cells in bone marrow and inflamed tissues. The research results have contributed to a better understanding of the immunological and molecular mechanisms in rheumatic diseases and their treatment. The identification of the long-lived memory plasma cell has led to promising treatment approaches with curative potential in autoimmune diseases.
Topics: Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Humans; Immunologic Memory; Plasma Cells; Rheumatic Diseases
PubMed: 35380249
DOI: 10.1007/s00393-022-01189-2 -
Clinical and Experimental Rheumatology 2017The Pain Management Task Force of the American College of Rheumatology published a report in 2010 highlighting pain management as a fundamental aspect of clinical... (Review)
Review
The Pain Management Task Force of the American College of Rheumatology published a report in 2010 highlighting pain management as a fundamental aspect of clinical practice, training and research. In the interim, the consideration of pain as a focus of attention of rheumatologists and rheumatology health professionals has become even more challenging than in 2010 because of the epidemic of opiate addiction and overdose death. The characterisation of categories of pain by mechanism (e.g., inflammation, joint degeneration, abnormalities of central pain processing) can help guide treatment. However, such categorisation can overlook the overlap of these processes and their interaction to create mixed pain states. Further complicating the assessment of pain, outcome measures in rheumatic disease often assess the degree of pain indirectly while concentrating on the quantification of inflammation. Non-inflammatory pain often persists despite treatment, highlighting the need for alternative analgesic therapies. Recommended therapies include acetaminophen, nonsteroidal anti-inflammatory drugs, and stimulators of the pain inhibitory pathway. Each of these non-opioid therapies has incomplete efficacy and potential toxicities that can limit their utility. Non-pharmacologic therapies can show efficacy that rivals or surpasses pharmacologic therapies in the control of pain and improving function in a variety of rheumatic disorders including chronic low back pain and fibromyalgia. A limitation of the use of these therapies is inadequate training and appreciation of their benefits. Furthermore, the supply of trained practitioners to provide non-pharmacological care and support patient efforts for self-management is often limited. Together, these considerations suggest the importance of a renewed effort to implement task force recommendations.
Topics: Biomedical Research; Humans; Osteoarthritis; Pain Management; Rheumatic Diseases; Rheumatic Fever; Rheumatology
PubMed: 28967362
DOI: No ID Found -
Drug Research Nov 2015
Topics: Humans; Rheumatic Diseases; Spondylarthritis
PubMed: 26536190
DOI: 10.1055/s-0035-1558061 -
Drug Research Nov 2015
Topics: Chronic Pain; Female; Germany; Humans; Male; Musculoskeletal Diseases; Rheumatic Diseases
PubMed: 26536188
DOI: 10.1055/s-0035-1558081 -
Drug Research Nov 2015
Topics: Cost of Illness; Humans; Musculoskeletal Diseases; Rheumatic Diseases
PubMed: 26536183
DOI: 10.1055/s-0035-1558059 -
Drug Research Nov 2015
Topics: Antirheumatic Agents; Epigenesis, Genetic; Humans; MicroRNAs; Rheumatic Diseases
PubMed: 26536181
DOI: 10.1055/s-0035-1558066 -
The Medical Clinics of North America Mar 2021Individuals with rheumatoid arthritis, systemic lupus erythematosus, or gout have increased risk of cardiovascular disease (CVD) compared with the general population.... (Review)
Review
Individuals with rheumatoid arthritis, systemic lupus erythematosus, or gout have increased risk of cardiovascular disease (CVD) compared with the general population. This risk relates to a combination of traditional cardiovascular risk factors and disease-specific factors. Screening for CVD is important because CVD contributes to significant morbidity and mortality. Management includes tight control of disease activity to reduce inflammation, but with care to minimize use of nonsteroidal anti-inflammatory drugs and prolonged courses of high-dose corticosteroids. Traditional cardiovascular risk factors should be managed with a combination of lifestyle interventions and pharmacotherapy. The decision to start antihypertensive and lipid-lowering therapy should be based on individual CVD risk.
Topics: Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Preventive Health Services; Rheumatic Diseases
PubMed: 33589100
DOI: 10.1016/j.mcna.2020.09.010